On December 29, Dobot, a Shenzhen-based robotics company listed in Hong Kong, unveiled its inaugural plan to issue Renminbi-denominated ordinary shares and seek a listing on the Shenzhen Stock Exchange. This move follows closely on the heels of BioCytus Pharmaceuticals' recent debut on the STAR Market. Other Hong Kong-listed entities, including DualityBio and Everbright International, have also embarked on initiatives to list on the A-share market, igniting a fervor among Hong Kong-listed firms to 'return to the A-share' realm. Notably, both Everbright International and Dobot hail from the Guangdong-Hong Kong-Macao Greater Bay Area. As these companies press ahead with their 'return to A-share' endeavors, it is anticipated that fresh exemplary (The word "demonstration" is replaced with "exemplary" here for a more natural expression in this context) cases of 'H-share to Shenzhen A-share' transitions will surface, delving deeper into and refining the specific practical approaches for this avenue. Since the onset of this year, the trend of A-share companies listing in Hong Kong has persisted unabated. Simultaneously, the enthusiasm among Hong Kong-listed firms to return to the A-share market has been steadily escalating.